On March 30, 2026, Lexeo Therapeutics, Inc. (Nasdaq: LXEO) announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside significant operational updates. The company reported cash, cash equivalents, and investments totaling $246.6 million, which it believes will support operations into 2028. For the fourth quarter, Lexeo recorded a net loss of $20.9 million, or $0.27 per share, compared to a net loss of $25.9 million, or $0.78 per share, for the same period in 2024. For the full year, the net loss was $100.0 million, or $1.86 per share, compared to $98.3 million, or $3.09 per share, in 2024.

The company highlighted several key operational milestones, including the submission of the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) to the FDA, which is expected to initiate in the first half of 2026. Lexeo also reported positive interim clinical data from ongoing Phase I/II studies of its lead candidate, LX2006, demonstrating an encouraging safety profile and meaningful cardiac benefits. The company has established a research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy, further enhancing its capabilities in cardiovascular medicine.

Lexeo's leadership team has been strengthened with the appointment of a new Chief Medical Officer, enhancing its expertise in cardiac development. The company is focused on disciplined execution as it advances its pipeline toward key milestones, aiming to drive long-term value for patients and shareholders.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.